Kai Zheng
Research Subjects
Kai Zheng has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ming Xu
Orthopedics Department, 960th Hospital of People's Liberation Army (PLA) Joint Service Support Force, China
2 shared publications - Xiuchun Yu
Orthopedic Department, 960 Hospital of People’s Liberation Army, China
2 shared publications - Baichuan Wang
Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication Bin Xu
Department of Orthopaedics, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710000, China
1 shared publicationChangcheng Chen
Department of Orthopaedics, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710000, China
1 shared publicationDongmei Yu
Department of Orthopaedics, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710000, China
1 shared publication
Latest Publications
- Open Access
- 11 October 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35, 102389
Ultrasound-responsive drug-carrying microbubbles combined with piezoelectric porous titanium scaffolds for the treatment of infected bone defects
- 11 October 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35, 102389
Open AccessUltrasound-responsive drug-carrying microbubbles combined with piezoelectric porous titanium scaffolds for the treatment of infected bone defects
- Open Access
- 2 November 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-7
Conservative surgery with microwave ablation for recurrent bone tumor in the extremities: a single-center study
Background: Surgical treatment for recurrent bone tumors in the extremities still presents a challenge. This study was designed to evaluate the clinical value of microwave ablation in the treatment of recurrent bone tumors. Methods: We present 15 patients who underwent microwave ablation for recurrent bone tumors during the last 7 years. The following parameters were analyzed for outcome evaluation: general condition, surgical complications, local disease control, overall survival, and functional score measured using the Musculoskeletal Tumor Society (MSTS) 93 scoring system. Results: Percutaneous microwave ablation in one patient with osteoid osteoma and another with bone metastasis resulted in postoperative pain relief. Thirteen patients received intraoperative microwave ablation before curettage or resection, including those with giant cell tumors of bone (6), chondroblastoma (2), osteosarcoma (2), undifferentiated sarcoma (1), and bone metastases (2). All patients achieved reasonable local tumor control in the mean follow-up of 29.9 months. The functional score was 24.1 for the 15 patients 6 months after the operation. Four patients had tumor metastasis and died, whereas 3 patients with tumors survived, and the remaining 8 patients without the disease survived. Conclusions: Microwave ablation represents an optional method for local control in treating recurrent bone tumors in the extremities.
- 2 November 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-7
Open AccessConservative surgery with microwave ablation for recurrent bone tumor in the extremities: a single-center study
Background: Surgical treatment for recurrent bone tumors in the extremities still presents a challenge. This study was designed to evaluate the clinical value of microwave ablation in the treatment of recurrent bone tumors. Methods: We present 15 patients who underwent microwave ablation for recurrent bone tumors during the last 7 years. The following parameters were analyzed for outcome evaluation: general condition, surgical complications, local disease control, overall survival, and functional score measured using the Musculoskeletal Tumor Society (MSTS) 93 scoring system. Results: Percutaneous microwave ablation in one patient with osteoid osteoma and another with bone metastasis resulted in postoperative pain relief. Thirteen patients received intraoperative microwave ablation before curettage or resection, including those with giant cell tumors of bone (6), chondroblastoma (2), osteosarcoma (2), undifferentiated sarcoma (1), and bone metastases (2). All patients achieved reasonable local tumor control in the mean follow-up of 29.9 months. The functional score was 24.1 for the 15 patients 6 months after the operation. Four patients had tumor metastasis and died, whereas 3 patients with tumors survived, and the remaining 8 patients without the disease survived. Conclusions: Microwave ablation represents an optional method for local control in treating recurrent bone tumors in the extremities.
- Open Access
- 28 June 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-8
Outcome of segmental prosthesis reconstruction for diaphyseal bone tumors: a multi-center retrospective study
The optimal reconstructive method after diaphyseal malignant bone tumor resection remains controversial. This multicenter clinical study was designed to investigate the clinical value and complications of segmental prosthesis in the repair of diaphyseal defects. We present 49 patients from three clinical centers treated with wide resection for primary or metastatic bone tumors involving the diaphysis of the femur, tibia, humerus, or ulna, followed by reconstruction using a modular intramedullary segmental prosthesis. Enrolled patients included 23 men and 26 women with a mean age of 63.3 years. Of these, seven patients had primary bone tumors and 42 patients had metastatic lesions. At the mean follow-up of 13.7 months, 17 patients were alive, 31 patients were deceased due to tumor progression, and one patient was dead of another reason. There were eight nononcologic complications (two with radial nerve injury, three with delayed incision healing, two with aseptic loosening in the proximal humerus prosthetic stem and one with structural failure) and three oncologic complications (three with primary tumor recurrence) among all patients. The incidence of complications in primary tumor patients (4/7, 57.1%) was higher than that in patients with metastatic tumors (7/42, 16.7%) (p = 0.036). Aseptic loosening and mechanical complications were not common for patients with primary tumors, although the reconstruction length difference was statistically significant (p = 0.023). No statistically significant differences were observed in limb function, while the mean musculoskeletal tumor society score was 21.2 in femora, 19.6 in humeri, and 17.8 in tibiae (p = 0.134). Segmental prostheses represent an optional method for the reconstruction of diaphyseal defects in patients with limited life expectancy. Segmental prostheses in the humerus experienced more complications than those used to treat lesions in the femur.
- 28 June 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-8
Open AccessOutcome of segmental prosthesis reconstruction for diaphyseal bone tumors: a multi-center retrospective study
The optimal reconstructive method after diaphyseal malignant bone tumor resection remains controversial. This multicenter clinical study was designed to investigate the clinical value and complications of segmental prosthesis in the repair of diaphyseal defects. We present 49 patients from three clinical centers treated with wide resection for primary or metastatic bone tumors involving the diaphysis of the femur, tibia, humerus, or ulna, followed by reconstruction using a modular intramedullary segmental prosthesis. Enrolled patients included 23 men and 26 women with a mean age of 63.3 years. Of these, seven patients had primary bone tumors and 42 patients had metastatic lesions. At the mean follow-up of 13.7 months, 17 patients were alive, 31 patients were deceased due to tumor progression, and one patient was dead of another reason. There were eight nononcologic complications (two with radial nerve injury, three with delayed incision healing, two with aseptic loosening in the proximal humerus prosthetic stem and one with structural failure) and three oncologic complications (three with primary tumor recurrence) among all patients. The incidence of complications in primary tumor patients (4/7, 57.1%) was higher than that in patients with metastatic tumors (7/42, 16.7%) (p = 0.036). Aseptic loosening and mechanical complications were not common for patients with primary tumors, although the reconstruction length difference was statistically significant (p = 0.023). No statistically significant differences were observed in limb function, while the mean musculoskeletal tumor society score was 21.2 in femora, 19.6 in humeri, and 17.8 in tibiae (p = 0.134). Segmental prostheses represent an optional method for the reconstruction of diaphyseal defects in patients with limited life expectancy. Segmental prostheses in the humerus experienced more complications than those used to treat lesions in the femur.